In targeted temperature management (TTM) postcardiac arrest, tighter temperature control is achieved with internal than external cooling, a study has shown. Moreover, internal cooling potentially results in better survival-to-hospital discharge outcomes and reduces cardiac arrhythmia complications in carefully selected patients as compared with normothermia.
One-third of dementia cases globally can be prevented by addressing nine lifestyle factors at different stages of life, beginning from better education during childhood, according to a report from The Lancet Commission on Dementia Prevention, Intervention, and Care.
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Patients with systemic lupus erythematosus (SLE) without cardiovascular conditions have impaired endothelial function, a new case-controlled study has shown. Factors that contribute to endothelial dysfunction include renal diseases and diastolic hypertension.
Stopping statins within 6 months after a first ischaemic stroke was associated with an increased risk of recurrent stroke at 1 year compared with those who continued with the therapy, a new study showed.
Genetic polymorphisms in CYP2C9 and VKORC1 affect the pharmacology and safety of warfarin, and patients with venous thromboembolism (VTE) who carry the said polymorphisms spend more time overanticoagulated, require a lower drug dose and are at increased bleeding risk with the drug, according to a pharmacogenetic subanalysis of the Hokusai VTE trial.
Adding sitagliptin, a dipeptidyl peptidase 4 inhibitor (DPP-4), to usual care in patients with glycaemic equipoise does not increase the risk of cardiovascular (CV) events in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), according to the TECOS* study.
Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated significant reductions in major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus (T2DM) at high cardiovascular (CV) risk in the LEADER (Liraglutide Effect and Action in Diabetes – Evaluation of Cardiovascular Outcomes Results) trial.
Newer metabolic agents, including trimetazidine, represent ancillary forms of prophylactic antianginal therapy and may be useful in patients with stable coronary artery disease (SCAD) who are unsuitable for percutaneous or surgical revascularization, says a leading cardiologist at the recent AFCC 2016.
Cardiovascular magnetic resonance (CMR) is a stronger predictor of major adverse cardiovascular events (MACE) compared with single-photon emission computed tomography (SPECT), according to the CE-MARC* study.